Surgical and other Treatments of Diabetic Macular Edema: An Update

International Ophthalmology Clinics

Volumn 44, Issue 1, 2004, Pages 139-160

  Christoforidis, John B ^b   D'Amico, Donald J ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; CORTICOSTEROID; GLUCOCORTICOID; TRIAMCINOLONE;

BLOOD RETINA BARRIER; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC RETINOPATHY; HUMAN; HYPERBARIC OXYGEN; HYPERTENSION; HYPOXIA; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETINA BLOOD FLOW; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; VITRECTOMY; VITREOUS BODY DETACHMENT;

ALDEHYDE REDUCTASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; GLUCOCORTICOIDS; HUMANS; HYPERBARIC OXYGENATION; LASER COAGULATION; MACULAR EDEMA, CYSTOID; VITRECTOMY;

EID: 0842332559     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404410-00015     Document Type: Conference Paper

References (142)

1. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7-16.
2. Tso MOM. Pathology of cystoid macular edema. Ophthalmology. 1982;89:902-915.
3. Wolter JR. The histopathology of cystoid macular edema. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1981;216:85-101.
4. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14:222-232.
5. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy IV. Diabetic macular edema. Ophthalmology. 1984;91:1464-1474.
6. Jones CW, Cunha-Vaz J, Zweig KO, et al. Kinetic vitreous fluorophotometry in experimental diabetes. Arch Ophthalmol. 1979;97:1941-1943.
7. Gillies MC, Su T, Stoyt J, et al. Effect of high glucose on permeability on retinal capillary endothelium in vitro. Invest Ophthalmol Vis Sci. 1997;38:635-642.
8. Antonetti DA, Barber AJ, Khin S, et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: Vascular endothelial growth hormone decreases occludin in retinal endothelial cells. State Retina Research Group. Diabetes. 1998;47:1953-1959.
9. Gardner TW. Histamine, ZO-1 and increased blood-retinal barrier permeability in diabetic retinopathy. Trans Am Ophthalmol Soc. 1995;93:583-621.
10. Tout S, Chan-Ling T, Hollander H, et al. The role of Mueller cells in the formation of the blood-retinal barrier. Neuroscience. 1993;55:291-301.
11. Mizutani M, Gerhardinger C, Lorenzi M. Mueller cell changes in human diabetic retinopathy. Diabetes. 1998;47:445-449.
12. Holopigian K, Seple W, Lorenzo M, et al. A comparison of photopic and scotopic electroretinogram changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1992;33:2773-2780.
13. Vinores A, Gadegbeker C, Campochiaro FA, et al. Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. Am J Pathol. 1989;134:231-235.
14. Senger D, Galli ST, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
15. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
16. Aiello LP, Bursell S-E, Clermont, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective b-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.
17. Adamis AP, Shima DT, Tolentino NJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization. Arch Ophthalmol. 1996;114:66-71.
18. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103:1820-1828.
19. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
20. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms and endothelial cell growth. J Clin Invest. 1994;98:2018-2026.
21. Xia P, Inguchi T, Kern I, et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes. 1994;43:1122-1129.
22. King GL. The role of protein kinase C activation in the development of vascular disease in diabetes. Cur Opin Endocrinol Diabetes. 1996;3:285-290.
23. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-77.
24. Funatsu H, Yamashita H, Ikeda T, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2001;133:537-543.
25. Kauffman DJH, vanMeurs JC, Mertens DAE, et al. Cytokines in vitreous humor: Interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1994;35:900-906.
26. Cohen T, Nahari D, Cerem LW, et al. Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271:736-741.
27. Funatsu H, Yamashita H, Shimizu E, et al. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina. 2001;21:469-477.
28. Chua CC, Hamdy RC, Chua BHL. Upregulation of vascular growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1998;1401:187-194.
29. McLeod DS, Lefer D, Merges C, et al. Enhanced expression of intercellular adhesion molecule-1 and p-selectin in the diabetic retina and choroid. Am J Pathol. 1995;147:642-664.
30. Hickam JB, Frayser R. Studies of the retinal circulation in man. Circulation. 1966;33:302-316.
31. Linsenmeier RA, Brown RD, McRipley MA, et al. Retinal hypoxia in long-term diabetic cats. Invest Ophthalmol Vis Sci. 1998;39:1647-1658.
32. Enden MK, Nyengaard JR, Ostrow E, et al. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Invest Ophthalmol Vis Sci. 1994;53:2968-2975.
33. Kristinsson JK, Gottfendsdottir MS, Stefansson E. Retinal vessel dilatation and elongation precedes diabetic macular edema. Br J Opthalmol. 1997;81:274-278.
34. Parving HH, Vibenti GC, Kern H, et al. Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism. 1983;32:993-999.
35. Abbasi M, Covantoni M, Chu L, et al. Adhesiveness of mononuclear cells to endothelium in patients with NIDDM. Diabetes. 1996;45(suppl):66.
36. Yoshida A, Feke GT, Morales-Stoppello J, et al. Retinal blood flow alterations during progression of diabetic retinopathy. Arch Ophthalmol. 1983;101:225-227.
37. Sebag J, Buckingham B, Charles MA, et al. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol. 1992;110:1472-1476.
38. Sebag J, Boulazs EA. Pathogenesis of CME: Anatomic considerations of vitreoretinal adhesion. Surv Ophthalmol. 1984;29(suppl):493-498.
39. Sebag J. Diabetic vitreopathy. Ophthalmology. 1996;103:205-206.
40. Jumper MJ, Embabi SN, Toth CA, et al. Electron immunocytochemical analysis of protein hyaloid associated with diabetic macular edema. Retina. 2000;20:63-68.
41. Lewis H. The role of vitrectomy in the treatment of diabetic macular edema. Am J Ophthalmol. 2001;131:123-125.
42. Jin M, Kashiwagi K, Iizuka Y, et al. Matrix metalloproteinase in human diabetic and nondiabetic vitreous. Retina. 2001;21:28-33.
43. Wallow IH. Repair of the pigment epithelial barrier following photocoagulation. Arch Ophthalmol. 1984;102:126-135.
44. Marshall J, Clover G, Rothery S. Some new findings on retinal irradiation by krypton and argon lasers. Doc Ophthalmol Proc Ser. 1984;36:21-27.
45. Stefansson E, Machemer R, de Juan E Jr, et al. Retinal oxygenation and laser treatment in patients with diabetic retinopathy. Am J Ophthalmol. 1992;113:36-38.
46. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1806.
47. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy report number 2. Ophthalmology. 1987;94:761-774.
48. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 4. Int Ophthalmol Clin. 1987;27:265-272.
49. Bresnick GH. Diabetic macular edema. Ophthalmology. 1986;93:989-997.
50. Bresnick GH. Diabetic maculopathy: A critical review highlighting diffuse macular edema. Ophthalmology. 1983;90:1301-1317.
51. Olk RJ. Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1986;93:938-950.
52. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology. 1991;98:1594-1602.
53. McHugh JDA. Marshall J, Ffytche TJ, et al. Macular photocoagulation of human retina with a diode laser: A comparative histopathological study. Laser Light Ophthalmol. 1990;3:11-28.
54. Berger JW. Thermal modeling of micropulsed diode laser retinal photocoagulation. Lasers Surg Med. 1997;20:409-415.
55. Friberg RJ, Karatza EC. The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. Ophthalmology. 1997;10-4:2030-2038.
56. Akduman L, Olk RJ. Diode (810 nm) versus argon green (514 nm) modified grid photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1997;104:1433-1441.
57. Lewis H, Schachat AP, Haimann MN, et al. Coroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology. 1990;97:503-510.
58. The Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy: The third report from the Diabetic Retinopathy Study. Arch Ophthalmol. 1979;97:654-655.
59. Schatz H, Madeira D, McDonald HR, et al. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109:1549-1551.
60. Guyer DR, D'Amico DJ, Smith CWO. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 1992;113:652-656.
61. Birch CJ. Defective colour vision in diabetic retinopathy before and after laser photocoagulation. Mod Probl Ophthalmol. 1978;19:326-329.
62. Klein R, Klein SK, Moss SE, et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260:2864-2871.
63. Marshall G, Garg SK, Jackson WE, et al. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology. 1993;100:1133-1139.
64. Teuscher A, Schnell H, Wilson PWF. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care. 1988;11:246-251.
65. Chase HP, Jackson WE, Hoops SL, et al. Glucose control and the renal and retinal complications of insulin dependent diabetes. JAMA. 1989;261:1155-1160.
66. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
67. Reichard P, Nilsson B, Rosenquist U. Retardation of the development of microvascular complications after long-term intensified insulin treatment. The Stockholm Diabetes Intervention Study. N Engl J Med. 1993;329:304-309.
68. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complication in Japanese patients with non-insulin dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
69. Prospective Diabetes Study UK. (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
70. Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol. 1998;116:874-886.
71. Royosarkar TK, Gupta A, Dash RJ, Dogra MR. Effect of insulin therapy on progression of retinopathy in noninsulin-dependent diabetes mellitus. Am J Ophthalmol. 1993;115:569-574.
72. Lopes de Faria JM, Jalkh AE, Trempe CL, et al. Diabetic macular edema: Risk factors and concomitants. Acta Ophthalmol Scand. 1999;77:170-175.
73. Vitale S, Maguire MG, Murphy RP, et al. Clinically significant macular edema in type I diabetes: Incidence and risk factors. Ophthalmology. 1995;102:1170-1176.
74. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J. 1998;317:703-713.
75. Chew EY, Klein ML, Ferris FL III, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study. ETDRS Report # 22. Arch Ophthalmol. 1996;114:1079-1084.
76. Klein BEK, Moss SE, Klein R, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98:1261-1265.
77. Klein BEK, Klein R, Moss SE. Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration? Am J Ophthalmol. 1999;128:652-654.
78. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study. Report #18. Invest Ophthalmol Vis Sci. 1998;39:233-252.
79. Qiao Q, Keinanen-Kiukaanniemi S, Laara E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol. 1997;50:153-158.
80. Berman DH, Friedman EA. Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoetin. Retina. 1994;14:1-5.
81. Aiello LM, Rand LI, Briones JC, et al. Nonocular clinical risk factors in the progression of diabetic retinopathy. In: Little HL, Jack RL, Patz A, Forsham PH, eds. Diabetic retinopathy. New York: Thieme-Verlas, 1983.
82. Murphy RP, Nanda M, Plotnick L, et al. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol. 1990;108:215-218.
83. Sinclair SH, Nesler C, Foxman B, et al. Macular edema and pregnancy in insulin-dependent diabetes. Am J Ophthalmol. 1984;97:154-167.
84. Duker JS, Brown GC, Bosley TM, et al. Asymmetric proliferative diabetic retinopathy and carotid artery disease. Ophthalmology. 1990;97:869-874.
85. Bierly JR, Dunn JP. Macular edema after carotid endarterectomy in ocular ischemic syndrome. Am J Ophthalmol. 1992;113:105-107.
86. Klein BE, Klein R, Moss SE. Exogenous estrogen exposure and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of DiabetIc Retinopathy. Diabetes Care. 1999;22:1984-1987.
87. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98 (suppl 5):757-765.
88. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.
89. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121:57-61.
90. Frank RN, Amin R, Kennedy A, Hohman TC. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch Ophthalmol. 1997;115:136-147.
91. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol. 1990;108:1234-1244.
92. vanGerven JM, Boot JP, Lemkes HH, et al. Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Doc Ophthalmol. 1994;87:355-365.
93. Ogura Y, Kiryu J, Takahashi K, et al. Visual improvement in diabetic macular edema by hyperbaric oxygen treatment. Nippon Ganka Gakkai Zasshi. 1988;92:1456-1460.
94. Krott R, Heller R, Ainsenbrey S, et al. Adjunctive hyperbaric oxygenation in macular edema of vascular origin. Undersea Hyperb Med. 2000;27:195-204.
95. Schepens CL, Avila MP, Jalkh AE, et al. Role of the vitreous in cystoid;macular edema. Surv Ophthalmol. 1984;28(suppl):499-504.
96. Nasrallah FP, Van de Velde F, Jalkh AE, et alL. Importance of the vitreous in young diabetics with macular edema. Ophthalmology. 1989;96:1511-1517.
97. Lewis H, Abrams GW, Blumenkranz MS, et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99:753-759.
98. van Effenterre G, Guyot-Argenton C, Guiberteau B, et al. Macular edema caused by contraction of the posterior hyaloid in diabetic retinopathy. Surgical treatment of a series of 22 cases. J Fr Ophthalmol. 1993;16:602-610.
99. Harbour JW, Smiddy WE, Flynn HW Jr, et al. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol. 1996;121:405-413.
100. Pendergrast SD. Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid. Curr Opin Ophthalmol. 1998;9:71-75.
101. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol. 1996;122:258-260.
102. Otani T, Kishi S. Tomographic assessment of vitreous surgery for diabetic macular edema. Am J Ophthalmol. 2000;129:487-494.
103. Ikeda T, Sato K, Katano T, et al. Attached posterior hyaloid membrane and the pathogenesis of honeycombed cystoid macular edema in patients with diabetes. Am J Ophthalmol. 1999;127:478-479.
104. Kadonosono K, Itoh N, Ohno S. Perifoveal microcirculation before and after vitrectomy for diabetic cystoid macular edema. Am J Ophthalmol. 2000;130:740-744.
105. Yang CM. Treatment for severe diabetic macular edema. Am J Ophthalmol. 2000;129:487-494.
106. LaHeij EC, Hendrikse F, Kessels AG, et al. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch Clin Exp Ophthalmol. 2001;239:264-270.
107. Takagi H, Otani A, Kiryu J, et al. New surgical approach for removing massive foveal hard exudates in diabetic macular edema. Ophthalmology. 1999;106:249-256.
108. Tachi N, Hashimoto Y, Ogino N. Cystotomy for diabetic cystoid macular edema. Doc Ophthalmol. 1999;97(3-4):459-463.
109. Sato Y, Lee Z, Shimada H. Vitrectomy for diabetic cystoid macular edema. Nippon Ganka Gakkai Zasshi. 2001;105:251-256.
110. Sato Y, Lee Z, Shimada H. Vitrectomy for diabetic cystoid macular edema. Jpn J Ophthalmol. 2002;46:315-322.
111. Yamamoto T, Hitani K, Tsukahara I, et al. Am J Ophthalmol. 2003;135:14-19.
112. Yamomoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: The role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol. 2001;132:369-377.
113. Gandorfer A, Messmer EM, Ulbig MW, et al. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20:126-133.
114. Gandorfer A, Messmer EM, Ulbig MW, et al. Indocyanine green selectively stains the intemal limiting membrane. Am J Ophthalmol. 2001;131:387-388.
115. Gandorfer A, Haritoglou C, Gass CA, et al. Indocyanine green-assisted peeling of the internal limiting membrane may cause retinal damage. Am J Ophthalmol. 2001;132:431-435.
116. Haritoglou C, Gass CA, Schaumberger M, et al. Macular changes after peeling of the internal limiting membrane in macular hole surgery. Am J Ophthalmol. 2001;132:363-368.
117. Sippy BD, Engelbrecht NE, Hubbard GB, et al. Indocyanine green effect on cultured human retinal pigment epithelial cells: Implication for macular hole surgery. Am J Ophthalmol. 2001;132:433-435.
118. Engelbrecht NE, Freeman J, Sternberg P Jr, et al. Retinal pigment epithelial changes after macular hole surgery with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol. 2002;133:89-94.
119. Stalmans P, VanAken EH, Veckeneer M, et al. Toxic effect of indocyanine green on retinal pigment epithelium related to osmotic effects of the solvent. Am J Ophthalmol. 2002;134:282-285.
120. Terasaki H, Miyake Y, Nomura R, et al. Focal macular ERGs in eyes after removal of macular ILM during macular hole surgery. Invest Ophthalmol Vis Sci. 2001;42:229-234.
121. Kumagai K, Ogino N, Furukawa M, et al. Internal limiting membrane peeling in vitreous surgery for diabetic macular edema. Nippon Ganka Gakkai Zasshi. 2002;106:590-594.
122. Massin P, Duguid G, Erginay A, et al. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol. 2003;135:169-177.
123. Kaiser PK, Riemann CD, Sears JE, et al. Macula traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol. 2001;131:44-49.
124. Stefansson E, Landers MB 3rd, Wobarsht ML. Increased retinal oxygen supply following panretinal photocoagulation and vitrectomy and lensectomy. Trans Am Ophthal Soc. 1981;79:307-334.
125. Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 2001;79:435-440.
126. Wilson CA, Benner JD, Berkowitz BA, et al. Transcorneal oxygenation of the preretinal vitreous. Arch Ophthalmol. 1994;112:839-845.
127. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538-1544.
128. Marsh S, Nakhoul FM, Skorecki K, et al. Hypoxic induction of vascular endothelial growth factor is markedly decreased in diabetic individuals who do not develop retinopathy. Diabetes Care. 2000;23:1375-1380.
129. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science. 1999;285:245-254.
130. Hollinshead MB, Spillert CR, Lazaro EJ. Procoagulant effect of aqueous humor on in vitro clotting of blood and plasma. Curr Eye Res. 1988;8:819-824.
131. Hanashima C, Namiki H. Reduced viability of vascular endothelial cells by higher concentration of ascorbic acid in vitreous humor. Cell Biol Int. 1999;23:287-298.
132. Verstraeten T, Chapman C, Hartzer M, et at. Pharmacologic induction of PVD in the rabbit. Arch Ophthalmol. 1993;111:849-854.
133. Williams JG, Trese MT, Williams GA, et al. Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Ophthalmology. 2001;108:1902-1906.
134. Tezel TH, Priore LVD, Kaplan HJ. Posterior vitreous detachment with dispase. Retina. 1998;18:7-15.
135. Hageman GS, Ressel SR. Chondroitinase-mediated dissection of the primate vitreous body [abstract]. Invest Ophthalmol Vis Sci. 1994;35:1260.
136. Frank RN. Potential new medical therapies for diabetic retinopathy: Protein kinase C inhibitors. Am J Ophthalmol. 2002;133:693-698.
137. Tachi N, Hashimoto Y, Ogino N. Vitrectomy for macular edema combined with retinal vein occlusion. Doc Ophthalmol. 1999;97(3-4):465-469.
138. Wiechens B, Reichelt JA, Urbat C, et al. Pars plana vitrectomy in cystoid macular edema of different forms of chronic uveitis. Ophthalmologe. 2003;100:33-43.
139. Wiechens B, Nolle B, Reichelt JA. Pars-plana vitrectomy in cystoid macular edema associated with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol. 2001;239:474-481.
140. Stavrou P, Baltatzis S, Letko E, et al. Pars plana vitrectomy in patients with intermediate uveitis. Ocul Immunol Inflamm. 2001;9:141-151.
141. Kiryu J, Kita M, Tanabe T, et al. Pars plana vitrectomy for cystoid macular edema secondary to sarcoid uveitis. Ophthalmology. 2001;108:1140-1144.
142. Peyman GA, Canakis C, Livir-Rallatos C, et al. The effect of internal limiting membrane peeling on chronic recalcitrant pseudophakic cystoid macular edema: A report of two cases. Am J Ophthalmol. 2002;133:571-572.